Calviri products

Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available solutions.

Calviri’s Immunosignature (IMS) Technology is universally applicable to the development of diagnostic products. It is based on the recognition that combinatorial peptide sequences provide a richer source of possible antibody binding ligands than proteomic sequences, which are highly redundant. The diversity of antibody specificities is far greater than the diversity of proteomes. The IMS Technology enables an individual’s immense antibody repertoire to be broadly queried and reproducibly measured.